© 2005 European Society for Medical Oncology
Invited Paper |
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study
1 Department of Oncology-Regional Reference Center for the Biomolecular Characterization of Neoplasms and Genetic Screening of Hereditary Tumors, 2 Institute of Experimental Medicine, 4 Institute of Pathology, Università di Palermo, Palermo, Italy; 3 Epidemiological Observatory Center of Sicilian Region, Palermo, Italy; 5 Unit of Medical and Experimental Oncology, National Cancer Institute of Bari, Bari, Italy.
* Correspondence to: Dr Antonio Russo, Via Veneto 5, 90144 Palermo, Italy. Tel: +39 0916552500/2509; Fax: +39 0916554529; Email: lab-oncobiologia{at}usa.net
Background:: Although Ki-ras and TP53 mutations have probably been the genetic abnormalities most exhaustively implicated and studied in colorectal cancer (CRC) progression, their significance in terms of disease relapse and overall survival has not yet clearly been established.
Patients and methods:: A prospective study was carried out on paired tumor and normal colon tissue samples from a consecutive series of 160 previously-untreated patients, undergoing resective surgery for primary operable sporadic CRC. Mutations within the TP53 (exons 5–8) and Ki-ras (exon 2) genes were detected by PCR-SSCP analyses following sequencing.
Results:: Mutation analyses of exons 5 to 8 of the TP53 gene showed mutations in 43% (68/160) of the cases, while mutation analyses of exon 2 of the Ki-ras gene showed mutations in 46% (74/160) of the cases. Multivariate analyses showed that clinical outcome were strongly associated with the presence of specific TP53 mutations in L3 domain alone (only in DFS) or in combination with specific Ki-ras mutations at codon 13.
Conclusion:: Specific TP53 mutations in L3 domain alone (only in DFS) or in combination with specific Ki-ras mutations at codon 13 are associated with a worse prognosis in sporadic CRC.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer N. Engl. J. Med., October 23, 2008; 359(17): 1757 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Andersen, C. Wiuf, M. Kruhoffer, M. Korsgaard, S. Laurberg, and T. F. Orntoft Frequent occurrence of uniparental disomy in colorectal cancer Carcinogenesis, January 1, 2007; 28(1): 38 - 48. [Abstract] [Full Text] [PDF]
|
|